FDA accepts review of Biohaven’s NDA for zavegepant nasal spray
Zavegepant nasal spray is claimed to be the only small molecule calcitonin gene-related peptide (CGRP) receptor antagonist in an intranasal formulation for the acute treatment of migraine in